CBX-12 consists of the pH-sensitive peptide, a self-immolating linker, and the topoisomerase 1 (TOP1) inhibitor exatecan. Methods: In this Phase 1 trial, cohorts of pts were treated with …

Cybrexa has synthesized and developed CBX-12, an alphalexTM conjugate of the potent topoisomerase inhibitor, exatecan. CBX-12 provides additional proof of mechanism to the …

CBX-12是一种处于临床阶段的FIC多肽偶联药物（PDC），它利用Cybrexa专有的alphalex™技术增强了依喜替康对肿瘤细胞的递送，由pH低插入肽（pHLIP®）、连接体和依沙替康组成。

CBX-12 is a first-in-class PDC that uses Cybrexa’s proprietary alphalex™ technology to enhance the delivery of exatecan, a potent, established topoisomerase 1 (TOP1) inhibitor, directly to …

CBX-12 consists of the pH-sensitive peptide, a self-immolating linker, and the topoisomerase 1 (TOP1) inhibitor exatecan. Method: In a Phase 1 trial, cohorts of patients were treated with …

2021年1月28日 · CBX-12一种新型的实体肿瘤治疗药物，包含一种强效拓扑异构酶I抑制剂效应分子，与抗体药物偶联物（ADC）ENHERTU®和TRODELVY™使用的效应分子属于同一类别。 …

2024年5月29日 · Here we report our new pharmacodynamic (PD) biomarker-driven pilot study of CBX-12 in patients with advanced solid tumors. The primary objective of this study is to …

CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self …

CBX-12 is an alphalex conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its ground-breaking efficacy and safety profile …

CBX-12 is an alphalex TM conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 has demonstrated strong efficacy and a solid safety profile in preclinical …